| Symbol | GPCR |
|---|---|
| Name | STRUCTURE THERAPEUTICS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | United States |
| Telephone | (650) 457-1978 |
| Fax | — |
| — | |
| Website | https://www.structuretx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001888886 |
| Description | Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing oral treatments for chronic metabolic and pulmonary conditions. It develops oral small molecule therapeutics for the treatment of various diseases, including those impacting the metabolic, cardiovascular, and pulmonary systems. Its initial focus is on G-protein-coupled receptors as a therapeutic target class. It is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor for the treatment of type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases. Specifically, it is advancing ANPA-0073, its biased agonist, targeting the apelin receptor. It is also developing LTSE-2578, an investigational oral small molecule LPA1R antagonist for the treatment of idiopathic pulmonary fibrosis. Additional info from NASDAQ: |
Berrios John Joseph 🟢 acquired 315.4K shares (1 derivative) of Structure Therapeutics Inc. (GPCR) at $17.54 ($3.1M) Transaction Date: Aug 06, 2026 | Filing ID: 000006
Read moreNew Form 3 - Structure Therapeutics Inc. <b>Filed:</b> 2026-08-07 <b>AccNo:</b> 0002148420-26-000005 <b>Size:</b> 8 KB
Read moreFMR LLC 🔴 sold 4.6M shares (3 derivative) of Structure Therapeutics Inc. (GPCR) Transaction Date: Jul 22, 2026 | Filing ID: 315240
Read moreLin Xichen 🟡 adjusted position in 23.6K shares (4 derivative) of Structure Therapeutics Inc. (GPCR) at $0.34 Transaction Date: Jul 14, 2026 | Filing ID: 000006
Read moreLin Xichen 🟡 adjusted position in 23.6K shares (3 derivative) of Structure Therapeutics Inc. (GPCR) at $0.34 Transaction Date: Jun 25, 2026 | Filing ID: 000005
Read more📋 XICHEN LIN (Officer) plans to sell 36K shares of Structure Therapeutics Inc. (at $48.16 each, total $1.7M) Filed: Jun 25, 2026 | ID: 006512
Read moreStructure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity
Read moreStructure Therapeutics Announces Participation in Upcoming Investor Conferences
Read more(10% Negative) STRUCTURE THERAPEUTICS INC. (GPCR) Reports Q2 2026 Financial Results
Read moreNew Form 424B5 - Structure Therapeutics Inc. <b>Filed:</b> 2026-05-07 <b>AccNo:</b> 0001104659-26-057160 <b>Size:</b> 220 KB
Read more